176 related articles for article (PubMed ID: 8981189)
21. Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma.
Hegyi M; Gulácsi A; Cságoly E; Csordás K; Eipel OT; Erdélyi DJ; Müller J; Nemes K; Lautner-Csorba O; Kovács GT
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1697-702. PubMed ID: 22652833
[TBL] [Abstract][Full Text] [Related]
22. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
23. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
Eselgrim M; Grunert H; Kühne T; Zoubek A; Kevric M; Bürger H; Jürgens H; Mayer-Steinacker R; Gosheger G; Bielack SS
Pediatr Blood Cancer; 2006 Jul; 47(1):42-50. PubMed ID: 16206218
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy for the treatment of osteosarcoma of the limbs. Preliminary results in 100 patients treated preoperatively with high doses of methotrexate i.v. followed by cisplatin (i.a.) and adriamycin.
Bacci G; Picci P; Ruggieri P; Avella M; Mercuri M; Capanna R; Biagini R; Tienghi C; Mancini A; Brach del Prever A
Chir Organi Mov; 1991; 76(1):1-16. PubMed ID: 1893781
[TBL] [Abstract][Full Text] [Related]
25. Tumor volume increase during preoperative chemotherapy as a novel predictor of local recurrence in extremity osteosarcoma.
Song WS; Jeon DG; Kong CB; Cho WH; Koh JS; Lee JA; Yoo JY; Jung ST; Shin DS; Lee SY
Ann Surg Oncol; 2011 Jun; 18(6):1710-6. PubMed ID: 21222166
[TBL] [Abstract][Full Text] [Related]
26. Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study.
Bacci G; Ruggieri P; Picci P; Mercuri M; Ferraro A; Tella G; Ferrari S; Bertoni F; Comandone A
J Chemother; 1996 Feb; 8(1):70-81. PubMed ID: 8835114
[TBL] [Abstract][Full Text] [Related]
27. Variability in dose intensity of high-dose methotrexate for nonmetastatic osteosarcoma.
Leavey PJ; Mantadakis E; Maale G
Pediatr Hematol Oncol; 2002; 19(7):483-9. PubMed ID: 12217194
[TBL] [Abstract][Full Text] [Related]
28. [Progress and stagnation in chemotherapy protocols for primary osteosarcoma].
Delépine N; Alkallaf S; Cornille H; Markowska B; Delépine G
Ann Med Interne (Paris); 2003 Feb; 154(1):12-24. PubMed ID: 12746655
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.
Bacci G; Ferrari S; Longhi A; Forni C; Bertoni F; Fabbri N; Zavatta M; Versari M
J Chemother; 2001 Feb; 13(1):93-9. PubMed ID: 11233808
[TBL] [Abstract][Full Text] [Related]
30. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
32. Methotrexate pharmacokinetics and prognosis in osteosarcoma.
Graf N; Winkler K; Betlemovic M; Fuchs N; Bode U
J Clin Oncol; 1994 Jul; 12(7):1443-51. PubMed ID: 8021736
[TBL] [Abstract][Full Text] [Related]
33. Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study.
Bacci G; Gherlinzoni F; Picci P; Van Horn JR; Jaffe N; Guerra A; Ruggieri P; Biagini R; Capanna R; Toni A
Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1337-45. PubMed ID: 3493903
[TBL] [Abstract][Full Text] [Related]
34. [The importance of dose intensity in preoperative chemotherapy for osteosarcoma--retrospective analysis of a short intensive chemotherapy regimen preoperatively using high-dose methotrexate and cisplatinum].
Takahashi M; Katagiri H; Sato K; Sugiura H; Yamamura S; Fukaya N; Nakanishi K
Gan To Kagaku Ryoho; 1994 Mar; 21(4):459-64. PubMed ID: 8129386
[TBL] [Abstract][Full Text] [Related]
35. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
[TBL] [Abstract][Full Text] [Related]
36. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.
Ferrari S; Palmerini E; Staals E; Abate ME; Longhi A; Cesari M; Balladelli A; Pratelli L; Bacci G
J Chemother; 2009 Apr; 21(2):205-10. PubMed ID: 19423475
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience.
Saeter G; Wiebe T; Wiklund T; Monge O; Wahlqvist Y; Engström K; Forestier E; Holmström T; Stenwig AE; Willén H; Brosjö O; Follerås G; Alvegård TA; Strander H
Acta Orthop Scand Suppl; 1999 Jun; 285():74-82. PubMed ID: 10429627
[No Abstract] [Full Text] [Related]
38. [Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
Ferrari S; Orlandi M; Avella M; Caldora P; Ferraro A; Ravazzolo G; Bacci G
Minerva Med; 1992 May; 83(5):289-93. PubMed ID: 1589134
[TBL] [Abstract][Full Text] [Related]
39. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
40. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]